Premium
Tandem haematopoietic stem cell transplantation for High Risk relapsed/refractory Hodgkin Lymphoma: a LYSA study
Author(s) -
Deau Benedicte,
Amorim Sandy,
Perrot Aurore,
Quittet Philippe,
Cornillon Jerome,
Chaoui Driss,
Marolleau Jean P.,
Oberic Lucie,
Le Du Katell,
Fornecker LucMatthieu,
Tournilhac Olivier,
Veillard Anne S.,
Chaillol Isabelle,
Robin Marie,
Tamburini Jérôme,
Brice Pauline
Publication year - 2018
Publication title -
british journal of haematology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.907
H-Index - 186
eISSN - 1365-2141
pISSN - 0007-1048
DOI - 10.1111/bjh.15184
Subject(s) - medicine , brentuximab vedotin , transplantation , salvage therapy , refractory (planetary science) , surgery , population , hematopoietic stem cell transplantation , oncology , autologous stem cell transplantation , lymphoma , chemotherapy , hodgkin lymphoma , biology , astrobiology , environmental health
Summary Tandem stem cell transplantation ( SCT ) is an option for high‐risk relapsed/refractory Hodgkin Lymphoma ( HL ) patients. We evaluated the tolerance/efficacy of double autologous or autologous SCT ( ASCT ) followed by allogenic SCT (allo SCT ) in 120 HL patients prospectively registered on a French nationwide database. Median age was 26 (14–56) years. Complete remission rate was 60%, including 33% after a single line, and another 27% after two or more salvage regimens. Partial response rate was 32%, and 8% suffered treatment failure. Overall, 115 (96%) patients underwent a first ASCT , and 73 (61%) had a tandem SCT , including allo SCT in 44 (60%) and ASCT in 29 (40%). The median follow‐up was 43 months (4.8–73.7 months). The two‐year progression‐free survival rate for the whole population and for patients receiving tandem transplant was 56% (95% confidence interval [ CI ]: 46–65%) and 71% (95% CI : 49–84%), respectively. Among tandem transplants, we observed 20 deaths (17%), 10 of which were transplant‐related (6 allo SCT and 4 ASCT ). We suggest that tandem SCT is efficient in high‐risk relapsed/refractory HL patients, although transplant‐related mortality remains high. The benefit of tandem SCT should be balanced with the efficacy of Brentuximab vedotin‐based post‐transplant consolidative strategies in high‐risk relapsed/refractory HL patients.